Cyclacel Pharmaceuticals, Inc.
CYCC
$0.3449
-$0.0091-2.57%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 0.00 | 10.00K | 4.00K | 29.00K | 31.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00 | 10.00K | 4.00K | 29.00K | 31.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 0.00 | 10.00K | 4.00K | 29.00K | 31.00K |
| SG&A Expenses | 948.00K | 1.24M | 1.63M | 1.60M | 1.87M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.83M | 2.19M | 3.65M | 4.38M | 5.39M |
| Operating Income | -1.83M | -2.18M | -3.64M | -4.36M | -5.36M |
| Income Before Tax | -1.86M | -2.17M | -3.67M | -4.30M | -5.69M |
| Income Tax Expenses | 1.19M | -210.00K | -412.00K | -1.35M | -422.00K |
| Earnings from Continuing Operations | -3.05M | -1.96M | -3.26M | -2.95M | -5.27M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.05M | -1.96M | -3.26M | -2.95M | -5.27M |
| EBIT | -1.83M | -2.18M | -3.64M | -4.36M | -5.36M |
| EBITDA | -1.83M | -2.18M | -3.64M | -4.35M | -5.35M |
| EPS Basic | -0.33 | -0.91 | -1.80 | -2.27 | -6.23 |
| Normalized Basic EPS | -0.13 | -0.63 | -1.27 | -2.07 | -4.17 |
| EPS Diluted | -0.33 | -0.91 | -1.80 | -2.27 | -6.23 |
| Normalized Diluted EPS | -0.13 | -0.63 | -1.27 | -2.07 | -4.17 |
| Average Basic Shares Outstanding | 9.24M | 2.15M | 1.81M | 1.30M | 854.00K |
| Average Diluted Shares Outstanding | 9.24M | 2.15M | 1.81M | 1.30M | 854.00K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -0.95% |